Preval HealthPreval Health

Therapies

Monthly therapy updates

A script checks ClinicalTrials.gov, PubMed and openFDA every month and compares the result with the month before. Only papers that name the drug are listed. The newest run is October 27, 2026.

October 27, 2026

No changes since the previous run.

October 26, 2026

No changes since the previous run.

October 25, 2026

  • Enlicitide (publication): PMID 42870623: Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol.
  • Enlicitide (publication): PMID 42867105: Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
  • Lerodalcibep (publication): PMID 42788287: Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterol
  • Inclisiran (publication): PMID 42869405: Comparative Cardiovascular Outcomes Associated with Evolocumab Versus Inclisiran Among Patients with Elevated Lipoprotein(a).
  • Inclisiran (publication): PMID 42828262: Real-world treatment adherence and persistence among patients initiating inclisiran or PCSK9 mAbs.
  • Inclisiran (publication): PMID 42803952: Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network.
  • Inclisiran (publication): PMID 42793794: Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study.
  • Inclisiran (publication): PMID 42784009: The Utilization of Inclisiran for the Optimization of Lipid Management in People Living with HIV: A Clinical Case Series and Comprehensive R
  • Pelacarsen (publication): PMID 42886494: Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3-Now What?
  • Pelacarsen (publication): PMID 42880684: Pelacarsen and Lp(a)HORIZON: Interpreting the Disconnect Between Lipoprotein(a) Lowering and Cardiovascular Outcomes.
  • Obicetrapib (publication): PMID 42920302: Effect of Obicetrapib on Glycaemia and New-Onset Diabetes: Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of CETP Inhibit
  • Obicetrapib (publication): PMID 42866070: Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition.
  • Olezarsen (publication): PMID 42886196: Olezarsen Reduces Triglyceride Levels and the Risk of Acute Pancreatitis in People With Severe Hypertriglyceridemia.
  • Olezarsen (publication): PMID 42866822: Silencing apolipoprotein C-III to silence pancreatitis: olezarsen and the maturation of RNA-targeted therapy for severe hypertriglyceridemia
  • Olezarsen (publication): PMID 42837875: Olezarsen for the treatment of hypertriglyceridemia: A Bayesian reanalysis of randomized controlled trials.
  • Olezarsen (publication): PMID 42814299: Olezarsen for the Treatment of Hypertriglyceridemia.
  • Evinacumab (publication): PMID 42828246: Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia.